Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News | August 16, 2013
August 16, 2013 — Patient enrollment has been initiated in a post-market registry for the Combo Dual Therapy Stent to...
Xience Prime Orsiro Drug Eluting Stent BIO-GLOW II Clinical Study Biotronik Abbo
News | July 01, 2013
July 1, 2013 — Primary end-point results from the BIOFLOW-II clinical study demonstrating the non-inferiority of the...
News | June 24, 2013
June 24, 2013 — Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study...
News | June 11, 2013
June 11, 2013 — New long-term data from the DIVERGE clinical study, presented at EuroPCR 2013 by Principal Investigator...
Xience Xpedition 48 Abbott Vascular CE mark Europe
News | May 28, 2013
May 28, 2013 — Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System...
News | April 30, 2013
April 30, 2013 — Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral Stent...
Medtronic Resolute Drug Eluting Stent Dual Antiplatelet Therapy Clinical
News | March 28, 2013
March 28, 2013 — Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute...
News | March 20, 2013
March 20, 2013 — Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation...
News | February 28, 2013
February 28, 2013 — OrbusNeich announced that OrbusNeich Medical GmbH has commenced patent infringement actions in...
Medtronic Resolute Integrity Stent FDA Approval 34, 38 mm
Technology | February 25, 2013
February 25, 2013 — The U.S. Food and Drug Administration (FDA) has approved the 34 and 38 mm lengths of the Medtronic...
Feature | February 18, 2013
February 18, 2013 — Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum...
Biosensors BioMatrix

The LEADERS Trial showed that the Biosensors BioMatrix, a drug-eluting stent with a biodegradable abluminal polymer coating, was functionally equivalent to a regular nonbiodegradable stent.

Feature | February 04, 2013 | Kamran Zamanian, Ph.D.
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents,...
BioSensors International BioFreedom Drug Coated Stent CE mark
News | January 31, 2013
January 31, 2013 — Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS...
Feature | January 16, 2013
January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-...
Abbott Absorb bioresorbable stent
Feature | January 08, 2013
January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States....